{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T05:43:13Z","timestamp":1736314993070,"version":"3.32.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.cllc.2024.10.003","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T11:00:51Z","timestamp":1729076451000},"page":"e55-e62.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Perioperative Outcomes of Neoadjuvant Therapy in Resectable Lung Cancer Patients With Endobronchial Disease in the Era of Personalized Medicine"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4091-4638","authenticated-orcid":false,"given":"Joseph","family":"Seitlinger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devangi","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciano","family":"Bulgarelli-Maqueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Cools-Lartigue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Sirois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Ferri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Spicer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Najmeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.cllc.2024.10.003_bib0001","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: cancer J Clin"},{"key":"10.1016\/j.cllc.2024.10.003_bib0002","unstructured":"Statistics Canada. Accessed: ( January 4, 2022,). Lung cancer is the leading cause of cancer death in Canada. Available at: https:\/\/www.statcan.gc.ca\/o1\/en\/plus\/238-lung-cancer-leading-cause-cancer-death-canada."},{"key":"10.1016\/j.cllc.2024.10.003_bib0003","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1002\/cncr.35128","article-title":"Lung cancer statistics, 2023","volume":"130","author":"Kratzer","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2024.10.003_bib0004","unstructured":"American Cancer Society. Accessed: (January 12, 2023). Key Statistics for Lung Cancer. Available at: https:\/\/www.cancer.org\/cancer\/lung-cancer\/about\/key-statistics.html."},{"issue":"4","key":"10.1016\/j.cllc.2024.10.003_bib0005","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.ijrobp.2014.12.028","article-title":"Nodal stage of surgically resected non-small cell lung cancer and its effect on recurrence patterns and overall survival","volume":"91","author":"Varlotto","year":"2015","journal-title":"Int J Radiat Oncol biol Phys"},{"key":"10.1016\/j.cllc.2024.10.003_bib0006","unstructured":"National Comprehensive Cancer Network Accessed: (February 17, 2023). Non-small cell lung cancer, version 2.2023. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf."},{"issue":"9722","key":"10.1016\/j.cllc.2024.10.003_bib0007","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(10)60059-1","article-title":"Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data","volume":"375","author":"Arriagada","year":"2010","journal-title":"Lancet (London, England)"},{"issue":"9928","key":"10.1016\/j.cllc.2024.10.003_bib0008","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/S0140-6736(13)62159-5","article-title":"Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data","volume":"383","year":"2014","journal-title":"Lancet (London, England)"},{"issue":"1","key":"10.1016\/j.cllc.2024.10.003_bib0009","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S1470-2045(13)70334-6","article-title":"Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint","volume":"15","author":"Hellmann","year":"2014","journal-title":"The Lancet. Oncology"},{"issue":"16","key":"10.1016\/j.cllc.2024.10.003_bib0010","doi-asserted-by":"crossref","first-page":"8501","DOI":"10.1200\/JCO.2022.40.16_suppl.8501","article-title":"Nivolumab + chemotherapy versus chemotherapy as neoadjuvant treatment for resectable stage IIIA NSCLC: Primary endpoint results of pathological complete response (pCR) from phase II NADIM II trial","volume":"40","author":"Provencio-Pulla","year":"2022","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.cllc.2024.10.003_bib0011","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Medi"},{"issue":"31","key":"10.1016\/j.cllc.2024.10.003_bib0012","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.2217\/fon-2021-0549","article-title":"Neoadjuvant osimertinib with\/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA","volume":"17","author":"Tsuboi","year":"2021","journal-title":"Future Oncol (London, England)"},{"key":"10.1016\/j.cllc.2024.10.003_bib0013","first-page":"1","article-title":"Treatment sequencing in resectable lung cancer: the good and the bad of adjuvant versus neoadjuvant therapy","volume":"42","author":"Provencio","year":"2022","journal-title":"Am Soc Clin Oncol Educ book"},{"key":"10.1016\/j.cllc.2024.10.003_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.728519","article-title":"Lobar gross endobronchial disease predicts for overall survival and grade 5 pulmonary toxicity in medically inoperable early stage non-small cell lung cancer patients treated with stereotactic body radiation therapy","volume":"11","author":"Aghdam","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2024.10.003_bib0016","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1378\/chest.111.1.115","article-title":"Obstructive atelectasis in patients with small cell lung cancer. Incidence and response to treatment","volume":"111","author":"Vaaler","year":"1997","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.cllc.2024.10.003_bib0017","doi-asserted-by":"crossref","first-page":"768","DOI":"10.21037\/jtd.2017.02.88","article-title":"Prognostic effects of preoperative obstructive pneumonitis or atelectasis and comparison with tumor size in non-small cell lung cancer","volume":"9","author":"Pang","year":"2017","journal-title":"J Thor Dis"},{"issue":"2","key":"10.1016\/j.cllc.2024.10.003_bib0018","first-page":"93","article-title":"The Eighth Edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \"personalized\" approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA: Cancer J Clin"},{"issue":"3","key":"10.1016\/j.cllc.2024.10.003_bib0019","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jtho.2021.11.003","article-title":"The 2021 WHO classification of lung tumors: impact of advances since 2015","volume":"17","author":"Nicholson","year":"2022","journal-title":"J Thor Oncol"},{"issue":"5","key":"10.1016\/j.cllc.2024.10.003_bib0020","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.cllc.2024.10.003_bib0021","unstructured":"National Cancer Institute. Accessed: (November 27, 2017). Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. Available at: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_8.5x11.pdf."}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730424002080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730424002080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T01:35:26Z","timestamp":1736300126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730424002080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1525730424002080"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2024.10.003","relation":{},"ISSN":["1525-7304"],"issn-type":[{"type":"print","value":"1525-7304"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perioperative Outcomes of Neoadjuvant Therapy in Resectable Lung Cancer Patients With Endobronchial Disease in the Era of Personalized Medicine","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2024.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}